^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | EPZ015666 (PRMT5 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 2916: Protein arginine methyltransferase 5 as a therapeutic target for KRAS mutated colorectal cancer
Published date:
05/15/2020
Excerpt:
PRMT5 inhibitor treatment showed a significant reduction in cell viability in KRAS mutated cells compared to KRAS WT cells after 72 hours of treatment by High-Throughput Presto Blue HS Cell Viability Assay (at 1 µM 2.8-fold inhibition; p=0.00003 & at 10µM 2.1-fold; p=0.0025).
DOI:
10.1158/1538-7445.AM2020-2916
